The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Approaches to Inflammatory Myopathy

New Approaches to Inflammatory Myopathy

February 12, 2011 • By Vanessa Caceres

  • Tweet
  • Email
Print-Friendly Version / Save PDF
New Approaches to Inflammatory Myopathy

ATLANTA—Rheumatologists and health professionals reviewed the latest information on diagnosing and treating inflammatory myopathies during the ACR Clinical Symposium, “Inflammatory Myopathy Update,” here at the 2010 ACR/ARHP Annual Scientific Meeting. [Editor’s Note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.] The session’s three presentations focused on modalities to diagnose inflammatory myopathy, the role of autoantibodies in myositis, and exercise intervention.

You Might Also Like
  • Autoantibodies in Autoimmune Myopathy
  • Inflammatory Myopathies Difficult to Diagnose, Treat
  • Myopathies
Explore This Issue
February 2011
Also By This Author
  • Precision Medicine in Lupus

Diagnosing Inflammatory Myopathy

John A. Carrino, MD, MPH, associate professor of radiology and orthopaedic surgery and section chief of musculoskeletal radiology at Johns Hopkins University in Baltimore, started the session by reviewing some of the clinical features that usually point to myositis, including Gottron’s papules, the body symmetry of the disorder, proximal limb and truncal weakness, Raynaud’s disease, arthritis, and lung disease. He also pointed out clinical features that typically lead away from a myositis diagnosis, such as family history, weakness related to exercise and eating, cranial nerve involvement, muscle cramping, and early atrophy or hypertrophy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

While polymyositis, dermatomyositis, and inclusion body myositis are most commonly considered with inflammatory myopathy, he noted that there are a host of other emerging myopathies, such as necrotizing myopathy, giant cell myositis, eosinophilic myositis, granulomatous myositis, and others.

In the mid-1970s, Bohan and Peter developed criteria for polymoyositis and dermatomyositis before the use of magnetic resonance imaging (MRI).1,2 However, these criteria had some limitations, such as poor specificity in distinguishing polymyositis from late-onset muscular dystrophies, omission of the possible diagnosis of inclusion body myositis, and the fact that inflammation seen on muscle biopsy is not necessarily specific for inflammatory myositis. “There may be other disorders that cause muscle inflammation,” Dr. Carrino said. Other diagnostic criteria subsequently emerged.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

MRI is typically used in myosititis to confirm diagnosis and help with the phenotype, to rule out myositis mimics, and to select the site of the muscle biopsy so as to make an accurate histologic diagnosis, Dr. Carrino said. During treatment, MRI can help follow disease progression and therapeutic response.

Sometimes, cases referred to the Johns Hopkins myositis center are not actually myositis but instead are muscular dystrophy, fasciitis, metabolic bone disease, or muscle strains.

—John A. Carrino, MD, MPH

Sometimes, cases referred to the Johns Hopkins myositis center are not actually myositis but instead are muscular dystrophy, fasciitis, metabolic bone disease, or muscle strains, he noted.

Advanced techniques for muscle MRI are not always used but include open-bore 3T MRI and MR spectroscopy, which may be helpful in the future for myositis diagnosis.

Autoantibodies

In his presentation, Harsha Gunawardena, MD, senior research fellow at the University of Bath in Bath, U.K., focused on the role of autoantibodies in myositis. Autoantibodies are now detected in about 70% of adult and 60% of juvenile inflammatory myopathy patients, he said. These autoantibodies include anti-p200/100, anti–Mi-2 dermatomyositis subtype, anti-p155, anti-SAE, and the anti-MDA5 dermatomyositis subtype. Although the signs and symptoms associated with each autoantibody may vary, they can include skin changes, the risk for interstitial pneumonia, and cancer. For example, more than 50% of patients who are anti-p155/140 positive have cancer, Dr. Gunawardena said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: 2010 ACR/ARHP Annual Scientific Meeting, Diagnostic Criteria, inflammatory myopathy, Pathogenesis, Research, rheumatologist, TreatmentIssue: February 2011

You Might Also Like:
  • Autoantibodies in Autoimmune Myopathy
  • Inflammatory Myopathies Difficult to Diagnose, Treat
  • Myopathies
  • For Myopathy Basic Diagnostic Rules Hold

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.